JP6278416B2 - 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 - Google Patents
置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 Download PDFInfo
- Publication number
- JP6278416B2 JP6278416B2 JP2015527915A JP2015527915A JP6278416B2 JP 6278416 B2 JP6278416 B2 JP 6278416B2 JP 2015527915 A JP2015527915 A JP 2015527915A JP 2015527915 A JP2015527915 A JP 2015527915A JP 6278416 B2 JP6278416 B2 JP 6278416B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- alkyl
- methyl
- pyridine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DYUWCULHUMHNBT-UHFFFAOYSA-N CC(C)N(C=C1C(NCc(cc2CC3)ccc2S3(=O)=O)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O Chemical compound CC(C)N(C=C1C(NCc(cc2CC3)ccc2S3(=O)=O)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O DYUWCULHUMHNBT-UHFFFAOYSA-N 0.000 description 1
- RZWAIBSJBXQFFE-UHFFFAOYSA-N CC(C)N(C=C1C(NCc2c[n](CCS3)c3n2)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O Chemical compound CC(C)N(C=C1C(NCc2c[n](CCS3)c3n2)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O RZWAIBSJBXQFFE-UHFFFAOYSA-N 0.000 description 1
- WPOULMWKCYZLCF-UHFFFAOYSA-N CC(C)N(C=C1C(O)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O Chemical compound CC(C)N(C=C1C(O)=O)C(C)=C(c2cccc(C(F)(F)F)c2)C1=O WPOULMWKCYZLCF-UHFFFAOYSA-N 0.000 description 1
- MZTMMQOZSYPHIH-UHFFFAOYSA-N CC(N(C1CC1)C=C(C(O)=O)C1=O)=C1Br Chemical compound CC(N(C1CC1)C=C(C(O)=O)C1=O)=C1Br MZTMMQOZSYPHIH-UHFFFAOYSA-N 0.000 description 1
- FEMUDLSDTXNMQA-UHFFFAOYSA-N CC(N(C1CC1)C=C1C(NCc(cc2)ccc2S(C)(=O)=O)=O)=C(c2cccc(C(F)(F)F)c2)C1=O Chemical compound CC(N(C1CC1)C=C1C(NCc(cc2)ccc2S(C)(=O)=O)=O)=C(c2cccc(C(F)(F)F)c2)C1=O FEMUDLSDTXNMQA-UHFFFAOYSA-N 0.000 description 1
- SGLQKTBCUFTAIF-UHFFFAOYSA-N CC(N(C1CCC1)C=C1C(O)=O)=C(c2cccc(C(F)(F)F)c2)C1=O Chemical compound CC(N(C1CCC1)C=C1C(O)=O)=C(c2cccc(C(F)(F)F)c2)C1=O SGLQKTBCUFTAIF-UHFFFAOYSA-N 0.000 description 1
- RAQPQWZIMXGPQE-UHFFFAOYSA-N CC(N(CCOC)C=C(C(O)=O)C1=O)=C1I Chemical compound CC(N(CCOC)C=C(C(O)=O)C1=O)=C1I RAQPQWZIMXGPQE-UHFFFAOYSA-N 0.000 description 1
- WWYZFCAXLRNUOH-UHFFFAOYSA-N CCC(C)N(C=C(C1O)C(O)=O)C(C)=C1Br Chemical compound CCC(C)N(C=C(C1O)C(O)=O)C(C)=C1Br WWYZFCAXLRNUOH-UHFFFAOYSA-N 0.000 description 1
- QQVBTKNDMODWRS-UHFFFAOYSA-N CCC(C)N(C=C1C(NCc(cc2)ccc2S(C)(=O)=O)=O)C(C)=C(c2cccc(C(F)F)c2)C1=O Chemical compound CCC(C)N(C=C1C(NCc(cc2)ccc2S(C)(=O)=O)=O)C(C)=C(c2cccc(C(F)F)c2)C1=O QQVBTKNDMODWRS-UHFFFAOYSA-N 0.000 description 1
- BGCVBGBLPWGTHT-UHFFFAOYSA-N CCC(CC)N(C=C(C(NCc(cc1)ccc1S(C)(=O)=O)=O)C1=O)C(C)=C1Br Chemical compound CCC(CC)N(C=C(C(NCc(cc1)ccc1S(C)(=O)=O)=O)C1=O)C(C)=C1Br BGCVBGBLPWGTHT-UHFFFAOYSA-N 0.000 description 1
- FIAJWAGYHNKMGV-ZDUSSCGKSA-N CC[C@H](C)N(C=C(C(NCc(cc1)ccc1S(C)(=O)=O)=O)C1=O)C(C)=C1[Br]=C Chemical compound CC[C@H](C)N(C=C(C(NCc(cc1)ccc1S(C)(=O)=O)=O)C1=O)C(C)=C1[Br]=C FIAJWAGYHNKMGV-ZDUSSCGKSA-N 0.000 description 1
- OHGNETQNATWUND-UHFFFAOYSA-N CSc1ccc(CN(C(c2c3cccc2)=O)C3=O)cc1F Chemical compound CSc1ccc(CN(C(c2c3cccc2)=O)C3=O)cc1F OHGNETQNATWUND-UHFFFAOYSA-N 0.000 description 1
- GRLZQNTVQPVFNC-UHFFFAOYSA-N Cc1nnc(CNC(C(C2=O)=CN(C3CCC3)C(C)=C2Br)=O)[o]1 Chemical compound Cc1nnc(CNC(C(C2=O)=CN(C3CCC3)C(C)=C2Br)=O)[o]1 GRLZQNTVQPVFNC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12181541 | 2012-08-23 | ||
| EP12181541.9 | 2012-08-23 | ||
| PCT/EP2013/067427 WO2014029832A1 (en) | 2012-08-23 | 2013-08-22 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526455A JP2015526455A (ja) | 2015-09-10 |
| JP2015526455A5 JP2015526455A5 (https=) | 2016-10-13 |
| JP6278416B2 true JP6278416B2 (ja) | 2018-02-14 |
Family
ID=46963419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527915A Active JP6278416B2 (ja) | 2012-08-23 | 2013-08-22 | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20140057920A1 (https=) |
| EP (1) | EP2888249B1 (https=) |
| JP (1) | JP6278416B2 (https=) |
| WO (1) | WO2014029832A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN114650819A (zh) | 2019-09-17 | 2022-06-21 | 美莱奥生物制药第四有限公司 | 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 |
| WO2021209740A1 (en) | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
| US11804467B2 (en) * | 2020-06-25 | 2023-10-31 | Micron Technology, Inc. | Radiative heat collective bonder and gangbonder |
| CN112920124B (zh) * | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| EP4419102A1 (en) | 2021-10-20 | 2024-08-28 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844732A (en) * | 1985-10-24 | 1989-07-04 | Daicel Chemical Industries Ltd. | Pyridine-3-carboxamide derivatives |
| EP1268484A1 (en) | 2000-03-17 | 2003-01-02 | Novo Nordisk A/S | Condensed imidazoles as histamine h3 receptor ligands |
| US7211595B2 (en) | 2000-11-30 | 2007-05-01 | Abbott Laboratories | Farnesyltransferase inhibitors |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| WO2009058076A1 (en) | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| EA017736B1 (ru) * | 2008-01-23 | 2013-02-28 | Бристол-Маерс Сквибб Компани | Соединения 4-пиридинона и их применение для лечения рака |
| US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| EP2261211A1 (en) * | 2009-05-20 | 2010-12-15 | Université de Lille 2 Droit et Santé | 1,4-dihydropyridine derivatives and their uses |
| CA2773618A1 (en) | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| US20110224229A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Novel Crystalline Form |
-
2013
- 2013-08-20 US US13/971,374 patent/US20140057920A1/en not_active Abandoned
- 2013-08-22 JP JP2015527915A patent/JP6278416B2/ja active Active
- 2013-08-22 EP EP13756033.0A patent/EP2888249B1/en active Active
- 2013-08-22 WO PCT/EP2013/067427 patent/WO2014029832A1/en not_active Ceased
-
2015
- 2015-09-02 US US14/843,254 patent/US9340507B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150376131A1 (en) | 2015-12-31 |
| US20140057920A1 (en) | 2014-02-27 |
| EP2888249A1 (en) | 2015-07-01 |
| JP2015526455A (ja) | 2015-09-10 |
| US9340507B2 (en) | 2016-05-17 |
| WO2014029832A1 (en) | 2014-02-27 |
| EP2888249B1 (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6278416B2 (ja) | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
| JP6319747B2 (ja) | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
| JP6278415B2 (ja) | 置換４−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
| JP6218860B2 (ja) | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 | |
| JP6130519B2 (ja) | 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用 | |
| JP2008526761A (ja) | 多環式ビス−アミドｍｍｐ阻害剤 | |
| JP2020522517A (ja) | バニン阻害薬としてのヘテロ芳香族化合物 | |
| JP6434528B2 (ja) | 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 | |
| WO1998009960A1 (en) | 2,4-disubstituted pyrimidine derivatives, process for producing the same, and medicinal compositions containing the same | |
| HK1230168B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 | |
| HK1230169B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 | |
| HK1230167B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160822 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160822 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6278416 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |